Practice Pearls

What can we help you find?
anticoagulants
Matthew Johnson, MD, and Paul Dobesh, PharmD, FCCP, BCPS, share some final thoughts on the dosing of DOACs in obese patients.
practice pearls
The panel of experts review the monitoring parameters for determining efficacy of DOACs.
anticoagulants
Experts discuss the recommendation in monitoring when using DOACs.
anticoagulants
The panel of experts in cardiology discuss the barriers with treatment of obese patients with DOACs. They also discuss the importance of education of their peers.
anticoagulant
Experts in cardiovascular disease discuss the lack of data supporting dose adjustment of DOACs because of weight.
 
anticoagulant
Paul Dobesh, PharmD, FCCP, BCPS, discusses the data regarding the use of DOACs in obese patients with VTE.
 
anticoagulant
Paul Dobesh, PharmD, FCCP, BCPS, shares data from several studies looking at the use of DOACs in the obese population.
The panel discusses the risks and benefits of warfarin in the use of thrombosis.
 
practice pearl
The panel of experts in cardiology share their insights and the implications of the ISTH 2016 statement for DOACs.
 
cardiovascular
Paul Dobesh, PharmD, FCCP, BCPS, reviews the ISTH 2016 statement regarding the avoidance of DOACs in the obese population.
 
cardiovascular
Experts in cardiovascular disease review the definition of obesity and morbid obesity as stated by the CDC. They provide some insights on the management of thrombosis risks.
anticoagulants
Paul Dobesh, PharmD, FCCP, BCPS, discusses the dosing differences among the DOAC agents.